Wegovy is also prescribed to treat a liver condition called metabolic dysfunction-associated steatohepatitis (MASH)
[1] Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia) Sikiric P, et al
Collectively, our de novo designed TYR-based therapeutic strategy established an integrative platform to leverage the catalytic activity of TYR to in situ generate various drugs, thereby overcoming the current treatment challenges for enhanced melanin-associated skin disease therapy
The STEP trials, which tracked over 4,500 participants, showed that stopping semaglutide often leads to weight regain within 612 months, with patients returning close to baseline body weight
10.2147/DDDT.S411211 30 GuoX.SuY.DuY.ZhangF.YuW.RenW.et al (2025)